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Severe lower respiratory tract infection (LRTI) in infants 
caused by respiratory syncytial virus (RSV) has been asso-
ciated with later pneumonia hospitalization among children. 
To determine risk for pneumonia after RSV hospitalization 
in infancy, we conducted a retrospective cohort analysis of 
2,813 infants admitted to a hospital in Kenya and identified 
readmissions for pneumonia among this group during early 
childhood (<60 months of age). Incidence of readmission 
for pneumonia was higher for children whose first admission 
as infants was for LRTI and who were <3 months of age 
than for children who were first admitted as infants for non-
LRTI, irrespective of RSV status. Incidence of readmission 
for pneumonia with wheeze was higher for children whose 
first admission involved RSV compared with those who 
had non-RSV LRTI. Excess pneumonia risk persisted for 
2 years after the initial hospitalization. Close postdischarge 
follow-up of infants with LRTI, with or without RSV, could 
help prevent severe pneumonia later in childhood.
Pneumonia is a major cause of illness and death among children <5 years of age in sub-Saharan Africa (1,2), 
and respiratory syncytial virus (RSV) is the most common 
viral cause of pneumonia and bronchiolitis in this age group 
(3,4). RSV infection in infancy is associated with other long-
term respiratory problems (5–10) and, in one study, with 
pneumonia (11). The magnitude and duration of the increased 
risk for pneumonia after RSV infection are poorly defined 
(12). In addition, it is not clear whether this association is 
specific to RSV or whether other causes of lower respiratory 
tract infection (LRTI) in infancy are also associated with 
later pneumonia (11). A study in The Gambia reported an 
increased incidence of hospital admission for pneumonia, 
measurable up to 3 years after discharge (11).
We report results of a retrospective cohort analysis of 
children admitted to a rural district hospital in Kenya using 
data from a prospective longitudinal clinical surveillance 
project nested within a health and demographic surveillance 
system (13). The cohort was defined as all infants admitted 
to the hospital during 9 RSV seasons during 2002–2010; the 
infants were classified into exposure groups on the basis of 
the clinical features of LRTI and laboratory diagnosis of RSV 
at the first admission. The main outcome was readmission to 
a hospital for pneumonia before the age of 5 years.
Methods
Study Population
The study took place in the pediatric wards of Kilifi 
District Hospital (KDH), a rural hospital on the Indian 
Ocean coast of Kenya. Since 2001, data on all pediatric 
admissions and discharges of children at KDH have 
been prospectively collected in real time through an 
integrated online data management system in FileMaker 
Pro (FileMaker, Inc., Santa Clara, CA, USA). Starting 
from April 16, 2002, we linked admission records to the 
individual residence status of each child at the date of 
illness onset within the Kilifi Health and Demographic 
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Surveillance System (KHDSS). The KHDSS covers a 
population of ≈250,000 living close to the hospital; ≈60% 
of pediatric admissions of children at KDH originate from 
KHDSS residents (13,14). The KHDSS fieldworkers 
enumerate births, deaths, and migrations (i.e., into, out of, 
and within the study area) every 4 months. 
Since January 2002, continuous surveillance for RSV 
has been conducted among all children <60 months of age 
admitted to KDH for LRTI (15). A nasal specimen (nasal 
wash by bulb or nasopharyngeal aspirate) is collected 
from each patient by trained medical assistants soon 
after admission (15,16) and assayed for RSV antigen by 
immunofluorescence antibody testing (Imagen Respiratory 
Syncytial Virus Kit; Oxoid Ltd., Hampshire, UK; or Light 
Diagnostics Respiratory Viral Screen DFA Kit; Millipore, 
Temecula, CA, USA), according to the manufacturer’s 
instructions.
For our study, the cohort was defined as residents 
of KHDSS admitted to KDH during the first year of life 
during RSV epidemics from April 16, 2002, through May 
31, 2010. We classified the cohort into those who did or 
did not have LRTI on their first (index) admission. Among 
those with LRTI, we further subdivided the children on the 
basis of RSV immunofluorescence antibody test results. 
Children with LRTI not tested for RSV were examined in 
preliminary analyses and consolidated into the negative 
RSV test group. The 3 exposure groups in the cohort were 
the RSV LRTI group, the other LRTI group, and the non-
LRTI group. Infants were excluded if they were admitted 
on the day of birth; had features of severe malnutrition 
(i.e., severe wasting, bipedal edema, or mid-upper arm 
circumference <11 cm); were born with low birthweight 
(<2.5 kg); had underlying congenital diseases; or remained 
in the hospital for >2 weeks. Evidence suggests that infants 
in these categories are at a higher risk for readmission and 
postdischarge death (17).
We used the linked databases of the KDH and KHDSS 
to determine which cohort members were subsequently 
readmitted to the hospital or died before their fifth 
birthday. The primary outcome was readmission to KDH 
for pneumonia. As secondary outcomes, we examined 
pneumonia with concurrent wheezing (a marker of 
hyperreactive airways), all-cause, and nonpneumonia 
readmissions, as well as all-cause mortality. The Kenya 
Medical Research Institute Scientific Steering Committee 
and the National Ethical Review Committee granted ethical 
approval for this study.
Definition of Terms
RSV epidemics were defined empirically as periods 
delimited by weeks in which >1 RSV cases were identified 
in our hospital surveillance and within which >3 RSV cases 
were found in any contiguous 3-week period, as described 
(15). Pneumonia was defined as history of cough or difficulty 
breathing and >1 of the following: fast breathing for age 
(>60 breaths/min if <2 months of age or >50 breaths/min 
if 2–11 months of age); lower chest wall indrawing; low 
oxygen saturation (<90%) by pulse oximetry; or inability 
to feed, prostration, or unconsciousness (18). LRTI was 
ascribed at first admission if the child met the criteria 
for pneumonia or if the clinician’s discharge diagnosis 
included pneumonia, asthma, or bronchiolitis.
Statistical Analysis
Data were analyzed by using STATA version 11.2 
(StataCorp, College Station, TX, USA). We used the 
Student t test, Mann-Whitney U test, c2 test, or Fisher 
exact test as appropriate. Admission to the cohort began 
at the date of first discharge and continued until the child 
reached 5 years of age, died, or migrated out of KHDSS, 
or until December 31, 2010, whichever was earliest. 
Cohort members who migrated back into the KHDSS were 
readmitted to the cohort at the date of in-migration. 
Incidence rates were calculated as the number of 
outcome events among cohort members divided by the 
sum of child-years at risk within the cohort. Incidence 
rate ratios (IRRs) for pneumonia readmission between the 
study groups were estimated by using Poisson regression 
with Lexis expansion, adjusting for covariates related to the 
index admission (age, sex, admission to high dependency 
unit [HDU], geographic sublocation of residence, hospital 
access, hypoxia [oxygen saturation <90% by pulse 
oximetry], duration of hospital stay) and the follow-up 
period (RSV epidemics, age, presence of >1 readmissions 
for diagnoses other than LRTI). A cutoff of 43 admissions 
per 1,000 child-years, which was the median incidence of 
all pediatric admissions to the KDH in 2007, was used to 
create a binary variable for hospital access by administrative 
sublocation within the KHDSS.
A multivariable Poisson regression model was 
developed by using a forward stepwise procedure, rejecting 
variables with a p value >0.05 in likelihood ratio tests. Risk 
factors were introduced in descending order of strength of 
association determined from the univariate analysis. We 
used a robust variance estimator (Huber-White sandwich 
estimator) to account for within-person correlation of 
outcomes. We also performed time-to-event analysis with 
multiple-failure per person and single failure per person 
(censoring at first readmission with pneumonia), treating 
death as a competing risk.
Results
Baseline Description at Recruitment
The study recruitment period spanned 9 RSV 
epidemics lasting a total of 217 weeks. During these 
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weeks, 2,813 infants who met the eligibility criteria were 
admitted to the hospital; 560 had RSV LRTI, 1,140 had 
other LRTI, and 1,113 did not have LRTI (non-LRTI 
group). Of the children included in the other LRTI group, 
341 (29.9%) were not tested for RSV. The baseline 
characteristics for children in the 3 groups are shown 
in Table 1.
Cohort Follow-up and Readmissions
The median durations of follow up (interquartile 
range) were 40.6 (21.4–57.8), 44.2 (22.0–57.6), and 43.9 
(20.6–57.1) months for the RSV LRTI, other LRTI, and 
non-LRTI groups, respectively. Nine children initially in 
the non-LRTI group and 16 in the other LRTI group were 
readmitted with RSV LRTI within first year of life, leading 
to their crossover to the RSV LRTI group, starting from the 
date of discharge for the readmission.
The RSV LRTI, other LRTI, and non-LRTI groups 
contributed 1,781.9, 3,693.8, and 3,550.0 child-years of 
observation (cyo), respectively; the number of associated 
readmissions was 231, 419, and 337, respectively. 
Discharge diagnoses are shown in online Technical 
Appendix Table 1 (wwwnc.cdc.gov/eid/article/1/12-
0940-Techapp/.pdf). Pneumonia accounted for 131 (57%) 
readmissions for the RSV LRTI group, 228 (54%) for the 
other LRTI group, and 119 (36%) for the non-LRTI group. 
The numbers of children with only 1 readmission for 
pneumonia were 58, 173, and 82 for the RSV LRTI, other 
LRTI, and non-LRTI groups, respectively; the numbers 
with >2 readmissions were 27, 34, and 15, respectively. A 
total of 62 (2.2%) children were admitted to the hospital 
during the follow-up period with laboratory-confirmed 
RSV infections, 12 (2.1%) in the RSV LRTI group, 17 
(1.5%) in the other LRTI group, and 33 (3.0%) in the non-
LRTI group. Invasive bacterial pathogens were detected 
in 8 (1.4%), 12 (1.1%), and 15 (1.3%) children in these 
groups, respectively.
Comparison of Readmission Rates between  
Exposure Groups
Adjusted IRRs comparing rehospitalization for pneu-
monia by exposure groups are shown in Table 2. The rate 
of readmission for pneumonia in the RSV LRTI group did 
not differ from that in the other LRTI group (IRR 1.14, 95% 
CI 0.85–1.53), even after excluding children who were not 
tested for RSV (IRR 0.99, 95% CI 0.73–1.34). We com-
bined data for the RSV and other LRTI groups to create 
an all-LRTI group, consisting of all children with prior ex-
posure to any LRTI; the incidence rate for readmission for 
pneumonia among these children was significantly higher 
than for those not exposed to LRTI (non-LRTI group) 
(p<0.001). The observed effect was modified by age at time 
of exposure among children whose index LRTI admission 
occurred at age <3 months (IRR 2.83, 95% CI 1.93–4.15) 
versus >3 months (IRR 1.39, 95% CI 0.99–1.96). An effect 
modification by age at the index admission for all LRTI in-
fants was also observed for all-cause readmissions but not 
for nonpneumonia readmissions (Table 2). The incidence 
rate relative to non-LRTI was 1.57 (95% CI 1.21–2.04) 
for children whose first admission occurred in the first 3 
months of life and 1.04 (95% CI 0.84–1.30) for older chil-
dren. Results from the time to first pneumonia readmission 
analysis accounting for death as a competing risk did not 
change the interpretation of the associations between LRTI 
exposure and later pneumonia readmissions; hence, only 
the multiple-failure regression results are reported.
Using non-LRTI children as the baseline group, IRRs 
for pneumonia with wheeze were 5.37 (95% CI 2.66–10.83) 
in the RSV LRTI group and 3.50 (95% CI 1.77–6.94) in the 
other LRTI group. These associations were not modified by 
age at first admission. IRR for pneumonia with wheeze was 
1.53 (95% CI 0.92–2.54) in the RSV LRTI group compared 
with the other LRTI group; excluding children whose RSV 
status was not known from the other LRTI group lowered 
IRR to 1.32 (95% CI 0.78–2.26). The mortality rate was 
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Table 1. Baseline characteristics of children in study of pneumonia hospitalizations after severe LRTI in infancy, by study group, at 
time of first admission in Kilifi District Hospital, coastal Kenya, April 16, 2002–May 31, 2010* 
Characteristics 
Initial hospitalization 
RSV LRTI, n = 560 Other LRTI, n = 1,140 Non-LRTI, n = 1,113 
Male 296 (52.9) 646 (56.7) 607 (54.5) 
Median age, mo (IQR) 3.7 (1.9–6.6) 4.6 (2.1–7.7) 4.7 (0.3–8.6) 
Children age <3 mo 241 (43.0) 406 (35.6) 489 (43.9) 
Median hospital stay, d (IQR) 4 (3–5) 3 (2–5) 4 (2–6) 
Malaria† 9 (1.6) 114 (10.0) 147 (13.2) 
Gastroenteritis 34 (6.1) 140 (12.3) 338 (30.4) 
Pneumonia with wheeze 95 (17.0) 125 (11.0) NA 
Bacteremia, no./n (%) 7/545 (1.3) 33/1,109 (3.0) 33/1,053 (3.1) 
Admission to high-dependency unit 18 (3.2) 89 (7.8) 79 (7.1) 
Good hospital access 326 (59.5) 621 (55.4) 636 (58.6) 
Hypoxia 44 (7.9) 95 (8.3) 17 (1.5) 
*Values are no. (%) except as indicated. Boldface indicates statistical significance in the respective group relative to the non-LRTI group. RSV, 
respiratory syncytial virus; LRTI, lower respiratory tract infection; IQR, interquartile range; NA, not applicable. 
†Indicates blood slide testing positive for malaria parasites. 
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significantly lower for RSV-exposed children compared 
with the non-LRTI (IRR 0.42, 95% CI 0.20–0.90) and other 
LRTI (IRR 0.39, 95% CI 0.18–0.82; p = 0.013) groups. 
The mortality rate increased in areas with good access to 
the hospital (IRR 1.76, 95% CI 1.16–2.67), and incidence 
rate of subsequent pneumonia after admission to HDU 
decreased compared with other categories (IRR 0.48, 95% 
CI 0.27–0.85) (Table 2).
Rates of readmission were highest immediately 
after discharge for all groups, 6/1,000 cyo for the non-
LRTI group and 13–15/1,000 cyo for the other LRTI 
and RSV LRTI groups, and decreased to <2/1,000 cyo at 
18–30 months after discharge (online Technical Appendix 
Figure). The differential in the incidence of pneumonia 
readmissions between LRTI groups and the non-LRTI 
group over time after discharge is shown as IRRs in 
Figure 1 and time-to-event profiles in Figure 2. The rate 
of readmission for pneumonia was higher for the all-LRTI 
group compared with that for the non-LRTI group up to 2 
years after discharge (log-rank test p value <0.001) (Figure 
1). The profiles for readmission with pneumonia (Figure 2, 
panel A) and pneumonia with wheeze (Figure 2, panel B) 
and for postdischarge death (Figure 2, panel C) show the 
associations reported in Table 2 to be sustained primarily 
during the first 12–24 months after discharge.
Discussion
Using detailed hospital-based data linked to a closely 
monitored population, we found no difference in the 
incidence of pneumonia hospitalization among children 
previously admitted for RSV-associated LRTI in infancy 
compared with those admitted for non-RSV associated 
LRTI. However, we did find elevated incidence of 
readmission for pneumonia among children admitted 
as infants for LRTI, with or without RSV diagnosis, 
compared with children admitted as infants for a non-LRTI 
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Table 2. Results of multivariable Poisson regression analyses for hospital readmission diagnoses and all-cause mortality among 
children initially hospitalized during infancy at Kilifi district hospital, coastal Kenya, April 16, 2002–May 31, 2010* 
Risk factor 
IRR (95% CI) 
Pneumonia† 
Pneumonia with 
wheeze‡ All readmissions Nonpneumonia 
All-cause 
mortality 
All LRTI§      
 Non-LRTI Referent     
 Patient age <3 mo 2.83 (1.93–4.15) NS  1.57 (1.21–2.04) 0.84 (0.69–1.02) NS  
 Patient age >3 mo 1.39 (0.99–1.96)  1.04 (0.84–1.30)   
LRTI      
 Non-LRTI Referent     
 RSV LRTI NS 5.37 (2.66–10.83) NS  NS  0.42 (0.20–0.90) 
 Other LRTI  3.50 (1.77–6.94)   1.09 (0.70–1.69) 
Patient age       
 <3 mo at first admission Referent     
 >3 mo at first admission NS 1.31 (0.79–2.15) NS 1.38 (1.11–1.71) 0.88 (0.57–1.35) 
Access to hospital      
 Poor Referent     
 Good  0.80 (0.62–1.02) 0.58 (0.35–0.98) 0.75 (0.63–0.89) 0.74 (0.60–0.91) 1.76 (1.16–2.67) 
Length of hospital stay, d      
 <7 d Referent     
 >7 d 1.31 (0.88–1.95) NS 1.21 (0.94–1.56) 1.11 (0.85–1.46) 2.45 (1.52–3.93) 
Admitted to HDU      
 No Referent     
 Yes 0.48 (0.27–0.85) NS 0.64 (0.44–0.94) 0.82 (0.52–1.29) NS  
Age at follow-up, mo      
 0–11 Referent     
 12–23 0.56 (0.45–0.68) 0.54 (0.35–0.82) 0.67 (0.58–0.77) 0.80 (0.65–0.99) 0.29 (0.17–0.49) 
 24–36 0.20 (0.14–0.28) 0.28 (0.13–0.60) 0.33 (0.27–0.41) 0.50 (0.39–0.65) 0.11 (0.05–0.25) 
 48–59 0.05 (0.03–0.09) 0.01 (0.002–0.10) 0.13 (0.10–0.17) 0.23 (0.17–0.30) 0.12 (0.06–0.23) 
Admission for non-LRTI      
 No Referent     
 Yes 1.92 (1.49–2.47) 1.44 (0.84–2.50) NS  NS  2.03 (1.32–2.67) 
Readmission      
 During Jan–Jun Referent     
 During Jul–Dec NS NS  NS  NS  0.60 (0.39–0.93) 
*Risk factors refer to state at the time of first admission, except the last 3 variables (age group in months, occurrence of >1 non-LRTI admissions, and 
readmission time), which refer to calendar time during follow-up. IRR, incidence rate ratio; LRTI, lower respiratory tract infection; NS, not statistically 
significant and thus excluded from the final model for the specified outcome; RSV, respiratory syncytial virus; HDU, high dependency unit. 
†Defined as history of cough or difficulty breathing and >1 of the following: fast breathing for age (>60 breaths/min if <2 months of age or >50 breaths/min 
if 2–11 months of age); lower chest wall indrawing; low oxygen saturation (<90%) by pulse oximetry; or inability to feed, prostration, or unconsciousness. 
‡Pneumonia with concurrent wheeze. 
§Combined group of children with RSV and other LRTI. IRRs (95% CIs) for readmission with pneumonia, pneumonia with wheeze, any readmission, 
nonpneumonia, and all-cause mortality comparing RSV LRTI vs. other LRTI group are 1.14 (0.85–1.53), 1.53 (0.92–2.54), 1.10 (0.89–1.37), 1.07 (0.82–
1.39), and 0.39 (0.18–0.82), respectively. 
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condition. The magnitude of this association was highest 
among children admitted in the first 3 months of life and 
decreased to nonsignificant levels in children >3 months of 
age at the first admission. Although the association between 
LRTI during infancy and readmission for pneumonia was 
unaffected by RSV status at first admission, the association 
between readmission for pneumonia with wheeze was 
greater among children whose previous admission was for 
RSV LRTI (5-fold) compared with children whose previous 
admission was for LRTI without RSV (3-fold). Only 
children who were admitted for LRTI at <3 months of age 
had higher incidence of all-cause readmission compared 
with those admitted for non-LRTI. The association was 
lost with no effect modification by age when pneumonia 
admissions at the index admission were excluded; 
this finding indicates that the later pneumonia was the 
main driver of the increased incidence of subsequent 
readmissions and the observed effect modification by age at 
index admission.
Although this study involves a retrospective analysis, 
it is based on a large, unique dataset from sub-Saharan 
Africa in which detailed and consistent data were collected 
prospectively. KDH is the main inpatient facility in this 
rural district of Kenya. Previous reports indicate a distance 
decay in access to KDH, but this would only influence the 
relative incidence rates between study groups if there was 
a differential in access by study groups (14,15). Although 
Cox regression would have provided a more flexible 
analysis method, the proportional hazards assumption was 
violated, and we therefore used Poisson regression with 
Lexis expansion. Alternative analyses accounting for death 
as a competing risk yielded no qualitative differences in the 
study results. To account for the time-dependent incidence 
(seasonal changes) of exposure to LRTI pathogens, we 
set the analysis time based on the calendar time in the 
survival analysis. Seasonal variation in exposure was 
also minimized by restricting cohort recruitment to RSV 
epidemic periods only.
Our findings are consistent with the results of 
similar studies in The Gambia (11,19) and elsewhere 
(6,9,11,20,21). Weber et al. reported a 3-fold increase 
in incidence of admission for pneumonia or wheezing in 
children with prior exposure to RSV infection compared 
with a community of age-matched neighborhood children 
(11). Their study suggested that the duration of increased 
risk for pneumonia after RSV LRTI in infancy waned by the 
end of the second year after discharge, a finding duplicated 
in our study. However, that study did not explore the 
differential incidence of pneumonia after non-RSV LRTI, 
nor did it explore the influence of age at first episode of 
LRTI. Our study also used a hospital-based comparison 
group for which risk for readmission with pneumonia 
might have been elevated. 
Prospective studies in Europe and the United States 
reported that the effects of RSV in infancy on respiratory 
sequelae decreased sharply during the first year of follow-
up and that, by 5 years after RSV infection, the association 
is insignificant (11,20,21). Other studies have reported 
persistence of increased respiratory disease up to 7 years 
(22) and 11 years (8) after RSV infection but not at 18 years 
after infection (5).
A second observational, age-matched, case–control 
study in The Gambia examining later lung problems in 
children after childhood (<5 years of age) admission for 
severe pneumonia reported inconclusive results (19). Even 
though the odds of lung disease were higher among the 
childhood pneumonia case-patients compared with controls 
(odds ratio 2.93, 95% CI 0.69–12.48), the study had severe 
limitations, including small sample size and potential bias 
(only 68 of 190 possible cases were traced).
Our findings suggest that, in addition to RSV infection, 
other etiologies of LRTI are associated with subsequent 
hospital admissions for pneumonia or wheeze. We offer 
2 possible explanations for this. First, children with an 
inherent predisposition to subsequent pneumonia or 
wheezing episodes, such as those with smaller airways 
(23–26) or with atopy (27), may also be more susceptible 
to viral LRTI in early infancy. Second, viral LRTI in early 
infancy could lead to structural lung damage or immune 
paresis that causes further pneumonia episodes with or 
without wheeze. The latter explanation has been reported 
for reactive airway disease (mainly manifested as wheeze) 
in relation to RSV predisposition (28–32).
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Figure 1. Incidence rate ratios (IRR) for readmission with pneumonia 
over follow-up time for each of 3 comparisons among children initially 
admitted during infancy to Kilifi District Hospital, coastal Kenya, April 
16, 2002–May 31, 2010. A) Respiratory syncytial virus (RSV) lower 
respiratory tract infection (LRTI) versus non-LRTI group; B) other 
LRTI versus non-LRTI group; C) all LRTI (RSV and other LRTI 
combined) versus non-LRTI group. Error bars indicate 95% CIs.
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In our study, RSV infection appeared to protect 
against death, but this conclusion is best explained in 
reverse. In the comparison group, children admitted to a 
hospital for conditions other than RSV were more likely 
to die subsequently than were children admitted for RSV. 
However, unlike some other viruses that cause severe 
conditions, RSV causes a highly infectious disease that 
affects most children and does not associate specifically 
with markers of chronic ill health. A similar phenomenon 
has been observed with malaria parasitemia, which is 
associated with a reduced postdischarge mortality rate 
when compared with admissions for other conditions (17).
Findings of an increased mortality rate among children 
residing in areas with good access to KDH, as well as 
decreased incidence of subsequent pneumonia following 
admission to HDU, were unexpected and counterintuitive. 
Good access was mainly in urban and periurban 
administrative areas of Kilifi; because urbanization is 
associated with high HIV prevalence, some of the access-
to-care effect may be attributable to HIV/AIDS, but our 
data lacked HIV results for all admissions to check this 
effect. The protective association between HDU treatment 
and later pneumonia may be explained because the HDU 
has no ventilators and mainly admits children with a 
nonrespiratory severe illness and because nonrespiratory 
disease does not have an association with later pneumonia.
We report that hospitalizations for severe LRTI in 
early infancy in Kenya are associated with increased risk 
for subsequent pneumonia. The phenomenon has been 
observed for RSV-associated severe LRTI but not for 
non-RSV severe LRTI. This raises questions about the 
underlying cause and, on a practical level, alerts clinicians 
that a child with LRTI in the first 3 months of life is at 
risk for readmission with severe respiratory disease over 
the period of 1–2 years after discharge. Parents of children 
with LRTI-related hospital admissions during infancy 
should be advised to be vigilant in the care of the child 
and to seek medical advice rapidly in the event of further 
respiratory symptoms. An effective outpatient follow-up 
for these children throughout early childhood might also 
be warranted. Larger cohorts and probe studies using 
interventions against LRTI in infancy (e.g., vaccines) will 
be pivotal for confirming the causality and the magnitude 
of the associations observed here and for determining the 
specificity of the infectious etiologies associated (or not 
associated) with later episodes of pneumonia.
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